LIPO · Lipella Pharmaceuticals Inc. · Executive Compensation
$0.00
+0.00 (+0.00%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These factors individually and collectively raise substantial doubt about the Company's ability to continue as a going concern. The accompanying unaudited condensed financial statements do not include any adjustments that may result from this uncertainty.”View the 10-Q filed Nov 14, 2025
Market Cap
$2,310
Shares
4.62M
Volume · Oct 2
594
Avg daily vol (3M)
19.71K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jonathan Kaufman | Chief Executive Officer | $323,383 |
| Michael Chancellor | Chief Medical Officer | $315,083 |
| Douglas Johnston | Chief Financial Officer | $260,000 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jonathan Kaufman | Chief Executive Officer | $913,800 |
| Michael Chancellor | Chief Medical Officer | $905,500 |
| Douglas Johnston | Chief Financial Officer | $67,500 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jonathan Kaufman | Chief Executive Officer | $913,800 |
| Michael Chancellor | Chief Medical Officer | $831,767 |
| Douglas Johnston | Chief Financial Officer | $12,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Lori A. Birder | Board of Directors | Resigned | 2026-02-04 |
| Naoki Yoshimura | Board of Directors | Retired | 2025-10-21 |
| Dr. Michael Chancellor | member of the Company's Board of Directors | Retired | 2025-10-09 |
| Lori Birder | member of the Board | Appointed | 2023-06-23 |
| Dr. David Battleman | Board | Resigned | 2023-06-01 |
| Daniel Cohen | member of the Board | Appointed | 2023-03-27 |